1535202-81-3

Basic information

• Product Name: methyl (1R,15S,17R,18R,19S,20S)-17-[(3,5-dimethoxy-4 {[(pyridin-4-ylmethoxy)carbonyl]oxy}phenyl)carbonyloxy]-6,18-dimethoxy-3,13-diazapentacyclo[11.8.0.0^2,10.0^4,9.0^15,20]henicosa-2⁽¹⁰⁾,4,6,8-tetraene-19-carboxylate
• Synonyms: methyl (1R,15S,17R,18R,19S,20S)-17-[(3,5-dimethoxy-4 {[(pyridin-4-ylmethoxy)carbonyl]oxy}phenyl)carbonyloxy]-6,18-dimethoxy-3,13-diazapentacyclo[11.8.0.0^2,10.0^4,9.0^15,20]henicosa-2⁽¹⁰⁾,4,6,8-tetraene-19-carboxylate
• CAS NO: 1535202-81-3
• Molecular Weight: 729.784
• Mol File: 1535202-81-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl (1R,15S,17R,18R,19S,20S)-17-[(3,5-dimethoxy-4 {[(pyridin-4-ylmethoxy)carbonyl]oxy}phenyl)carbonyloxy]-6,18-dimethoxy-3,13-diazapentacyclo[11.8.0.0^2,10.0^4,9.0^15,20]henicosa-2⁽¹⁰⁾,4,6,8-tetraene-19-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (1R,15S,17R,18R,19S,20S)-17-[(3,5-dimethoxy-4 {[(pyridin-4-ylmethoxy)carbonyl]oxy}phenyl)carbonyloxy]-6,18-dimethoxy-3,13-diazapentacyclo[11.8.0.0^2,10.0^4,9.0^15,20]henicosa-2⁽¹⁰⁾,4,6,8-tetraene-19-carboxylate(1535202-81-3)
• EPA Substance Registry System: methyl (1R,15S,17R,18R,19S,20S)-17-[(3,5-dimethoxy-4 {[(pyridin-4-ylmethoxy)carbonyl]oxy}phenyl)carbonyloxy]-6,18-dimethoxy-3,13-diazapentacyclo[11.8.0.0^2,10.0^4,9.0^15,20]henicosa-2⁽¹⁰⁾,4,6,8-tetraene-19-carboxylate(1535202-81-3)

Safety Data

• Hazardous Substances Data: 1535202-81-3(Hazardous Substances Data)

Upstream product

• 32919-24-7 carbonic acid 4-nitrophenyl ester pyridin-4-ylmethyl ester 
• 21432-74-6 methyl (1R,15S,17R,18R,19S,20S)-17-[(4-hydroxy-3,5-dimethoxyphenyl)carbonyloxy]-6,18-dimethoxy-3,13-diazapentacyclo[11.8.0.0^2,10.0^4,9.0^15,20]henicosa-2⁽¹⁰⁾,4,6,8-tetraene-19-carboxylate 

Relevant articles and documents

COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION

The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).